Mark Leeds, D.O.
Mark Leeds, D.O.
Understanding Low Dose Benzodiazepines: Misconceptions and Realities
Understanding Low Dose Benzodiazepines: Misconceptions and Realities
Understanding Low Dose Benzodiazepines: Misconceptions and Realities
Monday 1st July 2024
Mark Leeds, D.O., uncovers the misconceptions and risks surrounding low-dose benzodiazepines, offering practical advice for safer use and discontinuation.
10 minutes
Informative
Educational
Supportive
Eye-opening
Honest
About this podcast
Author:
Mark Leeds, D.O.
Overview:
Categories:
Innovative Treatments & Recovery Paths
Sobriety Toolkit
Family Recovery from Addiction
Navigating Intimate Relationships
Nutritional Pathways to Recovery
Links:
Visit site
Episodes:
375 (View all)
Do you want to link to this podcast?
Get the buttons here!The Realities of Low-Dose Benzodiazepines: What You Need to Know
Episode Overview
- Low-dose benzodiazepines can be misleading and risky.
- Newer benzodiazepines are much more potent than older ones.
- Even low doses can lead to tolerance and withdrawal.
- Accurate dose conversions are crucial for safe use.
- Patient education and gradual tapering are essential for discontinuation.
The term 'low-dose' can be misleading and give a false sense of safety.
Mark Leeds, D.O., an osteopathic physician with extensive experience in addiction treatment, takes a deep dive into the world of benzodiazepines in this episode. You'll hear about the often-misleading concept of 'low-dose' benzodiazepines and the real risks associated with these medications. Dr Leeds explains how pharmaceutical companies have historically downplayed the dangers by using terms like 'discontinuation syndrome' instead of 'withdrawal', and how this has led to misconceptions among patients and even healthcare providers.
The episode sheds light on the relative potency of different benzodiazepines, such as Xanax, Ativan, and Klonopin, compared to older ones like Valium. These newer medications can be up to 20 times more potent, making so-called low doses potentially misleading and dangerous. Dr Leeds also highlights the importance of tools like the Ashton equivalence table for accurate dose conversions. Safety concerns are a major focus, as even lower doses can lead to tolerance, physical dependence, and withdrawal syndromes.
Dr Leeds shares insights from Professor Heather Ashton, noting that the lowest commercially available doses of potent benzodiazepines are significantly higher than the safest recommended doses for discontinuation. For those on benzodiazepines, the episode offers practical advice on tapering methods, including gradual dose reduction and switching to longer-acting benzodiazepines. Dr Leeds emphasises the need for regular monitoring and patient education to minimise withdrawal symptoms and ensure safer discontinuation.
Finally, the episode touches on the role of research and advocacy in improving benzodiazepine prescribing practices. Organisations like the Benzodiazepine Information Coalition are highlighted for their efforts in raising awareness and promoting better guidelines. This episode is a must-listen for anyone looking to understand the complexities of benzodiazepine use and discontinuation. Whether you're a patient or a healthcare provider, you'll find valuable insights and practical advice to help navigate this challenging aspect of addiction treatment.